Topic: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Objectives: 

1. Discuss recent literature regarding standard of care for cervical cancer treatment

2. Review components of phases of clinical trials

3. Review cervical cancer staging

Speaker: Dr. Bailey Blair

Session date: 
10/28/2024 - 6:30pm to 8:00pm EDT
Location: 
See outlook invite
Greenville, SC 29605
United States
See map: Google Maps
Add to calendar: 
  • 1.50 AMA PRA Category 1 Credit(s)™
    The University of South Carolina School of Medicine Greenville designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The University of South Carolina School of Medicine Greenville is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  • 1.50 Attendance

Please login or register to take this course.